FDA Finalizes Patient Preference Information Guidance: PPI Scope Extended Across the Medical Device Total Product Life Cycle

Key Takeaways

In March 2026, the U.S. FDA issued the final guidance Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle, with a notice of availability published in the Federal Register on March 30, 2026. The guidance confirms that patient preference information (PPI) may be used across the total product life cycle in FDA decision-making, covering investigational device exemption (IDE) applications, Breakthrough Device designation requests, PMA applications, HDE applications, De Novo classification requests and 510(k) premarket notifications, as well as administrative and enforcement decisions. It replaces the 2016 guidance, which focused only on PMA, HDE and De Novo. FDA also explains which preference study methods suit which scenarios, how PPI is incorporated into decision summaries, and how such information may be presented in the labeling of certain devices.

Full Translation of the Core Content

Basic Information on the New Guidance

Patient preference information (PPI) is one of the evidence types FDA has advanced relatively quickly in recent years, and it is a rare arrangement in global regulation in which patients participate directly in benefit-risk judgments.

In March 2026, FDA issued a new version of this guidance.

The full title is Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle. It was jointly issued by FDA's Center for Devices and Radiological Health (CDRH) and Center for Biologics Evaluation and Research (CBER), is dated March 2026, and is a final guidance. The Federal Register published the notice of availability on March 30, 2026, under docket number FDA-2015-D-1580.

It replaces the 2016 version of the guidance. That earlier version covered only three pathways — PMA, HDE and De Novo applications — plus presentation in decision summaries and labeling. The new version broadens the scope considerably.

Where the Scope Has Been Extended

According to the wording of the Federal Register notice, PPI may be used throughout the device total product life cycle to inform FDA decision-making. The applicable points include:

• Investigational device exemption (IDE) applications;
• Breakthrough Device designation requests;
• PMA applications;
• HDE applications;
• De Novo classification requests;
• 510(k) premarket notifications.

Within this list, 510(k) is one of the newly included pathways. Small and medium-sized enterprises that rely on the 510(k) route should pay attention to this change: patient preference data may now enter the risk-benefit discussion.

The administrative and enforcement stages also deserve attention. The notice states that PPI may likewise be used in FDA decisions on administrative, enforcement or other actions. This step moves PPI beyond premarket and labeling scenarios into later stages of regulation.

Three Types of Content the Guidance Provides

FDA does three things in this document:

• It sets out the principles and concepts that should be considered when collecting and submitting PPI;
• It explains how FDA incorporates PPI into decision summaries;
• It provides recommendations on how certain devices may present this information in their labeling.

The guidance also specifically addresses methodology — that is, which preference study is more appropriate in which scenario. This is critical when designing a PPI study that can be accepted in review.

The boundary should be emphasized. The word "voluntary" appears in the title of the guidance: PPI is submitted voluntarily and is not a mandatory requirement. Companies may choose not to submit, but once they do, they must follow FDA's recommended methods and evidence standards.

Why the Update Now

In its official training materials, FDA states that this update fulfils a commitment under MDUFA V. In other words, it is not an ad hoc initiative but a work item already scheduled in the user fee agreement.

The practical implications for applicants are fairly direct. Previously, PPI functioned more as a value-added element; it now has a formal pathway spanning the total product life cycle. For devices whose intended use is directly patient-facing, whose outcome measures are relatively subjective, or which are themselves high-risk or address unmet needs, the value of this type of evidence becomes more evident.

AIMEILI Regulatory Interpretation

Evidence Strategy Is Being Reordered, Not Merely Expanded

For medical device companies intending to enter the U.S. market, this guidance is a reordering of evidence strategy. Consider the weight of the change. The 2016 version covered only three pathways — PMA, HDE and De Novo. The new version brings IDE applications, Breakthrough Device designation requests, 510(k) notifications, and administrative and enforcement decisions into scope. With more pathways available, PPI moves from a rare exception to a routinely usable category of evidence.

The Most Direct Impact for SMEs: The 510(k) Pathway

For small and medium-sized enterprises, the most direct landing point is 510(k). Many companies treat 510(k) as a purely technical comparison exercise and focus only on substantial equivalence. Now, if a product is directly patient-facing, or if its outcome measures are relatively subjective, a well-designed preference study may become differentiating material within the benefit-risk justification.

Three Questions Before Deciding Whether to Conduct PPI

• Does the product interact directly with patients?
• Does the clinical outcome depend on patients' subjective experience?
• Is the device high-risk or does it address an unmet need?

If two or more of these conditions are met, the option deserves serious assessment.

Method Matters More Than the Conclusion

If a company proceeds, method matters more than the result. FDA emphasises selecting a study method appropriate to the decision context and sets out the applicable boundaries of different methods. Once the study design does not match the context, even impressive data will struggle to enter review. We recommend planning the study design in parallel at the project initiation stage, rather than supplementing it after clinical data have been assembled.

Boundaries and Jurisdiction

The boundaries also need to be stated. PPI is submitted voluntarily and is not a mandatory item; it also cannot replace the core evidence of safety and effectiveness. Companies should position PPI as supplementary justification, not as a shortcut.

The applicable market must also be made clear. This is FDA's position and cannot be applied directly to the European Union, Saudi Arabia or Southeast Asia. Different markets do not accept patient evidence to the same degree or in the same form, so each must be assessed individually. Nothing in this article constitutes a commitment regarding the registration outcome of any specific product; FDA's original text remains the controlling reference.

One-Sentence Recommendation

Map the product portfolio first, then decide which products merit PPI — do not reverse the order.

Two Additional Operational Points

• PPI should preferably be discussed with FDA at the clinical protocol stage, so that the research question and the target population are aligned early and rework is avoided.
• Data must be able to connect back to a specific decision. The report should clearly state the method, sample, attribute design and limitations, rather than presenting only a preference ranking.

For products with existing 510(k) clearances, there is no need to start over. PPI can be added as incremental evidence at the next change, indication expansion, or post-market reassessment. This keeps the investment more controllable and makes it easier to link with existing technical documentation.

One final point: PPI strengthens a justification; it is not a route for avoiding substantive requirements. Build solid safety and effectiveness evidence first, then discuss preference data as an enhancement — the order cannot be reversed.

Business Impact for Manufacturers, Distributors and CROs

The main commercial implication is that PPI now needs to be considered at the portfolio and protocol planning stages, not added late in a submission. Companies whose U.S. strategy depends on 510(k) clearance, and whose devices are patient-facing or rely on subjective endpoints, face the clearest change in the evidence they may choose to present.

• Portfolio triage: identify devices that are patient-facing, endpoint-subjective, high-risk, or aimed at unmet needs, and rank them by how much a preference study could strengthen the benefit-risk argument.
• Evidence planning: budget and timeline for preference research should be planned alongside clinical and non-clinical evidence generation, since the study question, target population and attributes must be aligned with the intended decision.
• Existing clearances: holders of current 510(k) clearances can treat PPI as incremental evidence at the next change, indication expansion or post-market reassessment, which spreads cost and integrates more easily with current technical files.
• Multi-market programmes: because FDA acceptance of PPI does not automatically translate to the EU, Saudi Arabia or Southeast Asia, patient evidence strategies should be assessed market by market rather than assumed to be portable.
• CRO and service providers: demand is likely to grow for preference study design, instrument development, statistical analysis and documentation that meets FDA's methodological expectations — capability that should be built ahead of requests.

Sources and Scope of Verification

Source institutions: U.S. FDA final guidance, Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle (March 2026, jointly issued by CDRH and CBER); U.S. Federal Register notice of availability, 91 FR 15622; FDA topic page on Patient Preference Information (PPI) in Medical Device Decision Making; FDA CDRH training material on the final guidance.

• FDA final guidance: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/incorporating-voluntary-patient-preference-information-over-total-product-life-cycle
• Federal Register: Incorporating Voluntary Patient Preference Information Over the Total Product Life Cycle; Guidance; Availability (91 FR 15622): https://www.federalregister.gov/documents/2026/03/30/2026-06063/incorporating-voluntary-patient-preference-information-over-the-total-product-life-cycle-guidance
• FDA: Patient Preference Information (PPI) in Medical Device Decision Making: https://www.fda.gov/about-fda/division-patient-centered-development/patient-preference-information-ppi-medical-device-decision-making
• FDA CDRH training material: https://www.fda.gov/media/182631/download

Original publication date: 2026-03-30. Guidance issue date taken as the Federal Register publication date of March 30, 2026. Verification scope and access date: the FDA guidance entry page, the full Federal Register notice text, the FDA patient preference information topic page and the CDRH training material were accessed and verified on 2026-09-28.

Scope note: this article is an interpretation of publicly available regulatory information and does not constitute a conclusion or commitment regarding any specific product, company or registration application. Submission of PPI is voluntary. The specific study design, strength of evidence and timing of submission must be determined in light of the product and the relevant review pathway, and remain subject to FDA's official text and subsequent updates.

FAQ

Is patient preference information mandatory for U.S. medical device submissions?

No. PPI is voluntary, as the guidance title makes clear. Companies may choose not to submit PPI, and the absence of PPI does not by itself make a submission incomplete or unacceptable. However, if a company elects to submit PPI, it should follow FDA's recommended study methods and evidence standards, because the data will be assessed on that basis.

Which FDA pathways can now use PPI?

Under the final guidance, PPI may be used across the total product life cycle, including IDE applications, Breakthrough Device designation requests, PMA applications, HDE applications, De Novo classification requests and 510(k) premarket notifications, as well as FDA administrative, enforcement and other decisions. This is broader than the 2016 guidance, which covered only PMA, HDE and De Novo.

Does PPI replace safety and effectiveness evidence?

No. PPI cannot substitute for the core evidence of safety and effectiveness. It functions as supplementary justification that can inform the benefit-risk assessment, and the foundational evidence must be established first.

Can PPI be added for a device that already holds a 510(k) clearance?

Yes, in a targeted way. Rather than reopening the existing file, PPI can be introduced as incremental evidence at the next change, indication expansion or post-market reassessment, which keeps the investment more controllable and easier to align with existing technical documentation.

Does FDA's acceptance of PPI apply in other markets?

No. This is FDA's position and cannot be applied directly to the European Union, Saudi Arabia or Southeast Asia, where acceptance and required formats for patient evidence differ. The applicability of a patient preference strategy should be determined market by market.

Editorial Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team.

Source principles: priority is given to official regulatory agencies, international organisations, standards bodies and publicly available regulatory materials; industry media and project experience are used only as supporting judgement.

Scope of application: this article supports preliminary understanding, document preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, test conclusions or legal advice.

Continue Reading

• Next: UK MHRA issues guidance on ambient voice technology — transcription and summarisation are not medical devices; diagnostic decision-making is
• EU MDCG 2026-5 clarifies UDI allocation responsibility: under distributor own-brand arrangements, the UDI-DI must still sit with the manufacturer
• UK Health Bill: three amendments tabled in Parliament to reserve powers for a medical device licensing regime
• Australia proposes publishing medical device review information; consultation window closes on 2 October
• CMDE notices: NMPA Party Leadership Group conveys and studies the important instructions of General Secretary Xi Jinping; summary of learning and education work on establishing and practising a correct view of political performance
• 31 August 2026: NMPA Center for Medical Device Evaluation opens public consultation on the draft technical review points for clinical trials of implantable brain-computer interface systems (cursor interaction and control function via electronic devices)

Need to Assess Your Registration Pathway?

Please provide the product name, intended use, target markets and existing documentation base. AIMEILI can assist in determining the registration pathway, identifying documentation gaps and assessing compliance risk. Contact AIMEILI to discuss your project.